An EEG device for monitoring seizure discharges.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D E Maynard.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A device, the cerebral function monitor, provides a continuous record of the electrical activity of the brain occurring at frequencies from 2 to 15 Hz. It is relatively cheap, portable, and easy to use and interpret. The apparatus has proved of value in three circumstances: firstly, when the cerebral circulation is likely to be vulnerable during open heart surgery; secondly, as a measure of recovery or deterioration following brain damage or drug overdose; and thirdly, where information about more physiological changes in cerebral function is required, for instance when testing anaesthetic and hypnotic drugs.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The disposition and metabolism of 14C-tiaramide HCl was examined in four healthy male volunteers, after administration of a 200-mg dose in solution. The mean cumulative recovery of administered radioactivity was 91.3 +/- 2.9% (mean +/- SD) in urine an 6.0 +/- 1.5% in feces. The elimination was rapid, with 83.9% of the radioactivity extracted in urine in the first 12 hr. The unchanged tiaramide serum concentration curve showed monoexponential elimination with a half-life of 1.3 hr. Peak serum levels, of 1.6-2.2 micrograms/ml were attained between 0.5 and 1.5 hr after dosing. Tiaramide was extensively metabolized, with less than 1% excreted unchanged. Urinary metabolites (80-95% of the dose) were identified by mass-spectral comparison to authentic standards. Biotransformation resulted in production of the N-acetic acid N-oxide, N-acetic acid, O-glucuronide, N-oxide, and desethanol metabolites of tiaramide.